ArticleJournal of gastrointestinal oncology2025
Impact of postoperative chemotherapy on the prognosis of combined hepatocellular-cholangiocarcinoma: a retrospective study based on the SEER database.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a nomogram comprising GLUT1 and clinical characteristics for predicting overall survival in intrahepatic cholangiocarcinoma.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of postoperative chemotherapy in the survival of combined hepatocellular-cholangiocarcinoma (cHCC-CCA) remains undefined. This study investigated the impact of postoperative chemotherapy on patient survival. Methods: Patients with cHCC-CCA who underwent surgical resection between January 2004 and December 2020 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were divided into non-chemotherapy (n=138) and postoperative chemotherapy (n=59) groups. Survival analyses were performed using Kaplan-Meier methods, log-rank tests, and Cox proportional hazards models. Propensity score matching (PSM) was used to reduce selection bias. Results: Among 197 patients, median follow-up was 23 months. Median overall survival (OS) was 32 months [95% confidence interval (CI): 22.7-41.3], with 40 months (95% CI: 26.4-53.7) in the non-chemotherapy group versus 26 months (95% CI: 18.6-33.4) in the chemotherapy group; median cancer-specific survival (CSS) was 54 months (95% CI: 32.3-75.7) in the non-chemotherapy group versus 28 months (95% CI: 19.1-36.9) in the chemotherapy group. The 1-, 3-, and 5-year OS were 73.5%, 46.8%, and 37.4%, and CSS were 77.8%, 51.8%, and 43.8%, respectively. Postoperative chemotherapy did not significantly improve OS [hazard ratio (HR) =1.290, 95% CI: 0.850-1.956, P=0.20] or CSS (HR =1.420, 95% CI: 0.892-2.259, P=0.11) compared to no chemotherapy. Older age (51-74 Conclusions: Our study did not find a significant association between postoperative chemotherapy and improved prognosis in cHCC-CCA patients. Older age and higher T stage were associated with worse prognosis. Prospective studies evaluating postoperative chemotherapy and other adjuvant strategies are needed to improve outcomes for this rare tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.